Takeda
650 East Kendall Street
Cambridge
MA
02421
United States
Website: https://www.takeda.com/
Email: info@takeda.com
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1525 articles about Takeda
-
Seattle Genetics And Takeda Announce Publication Of Final Data From ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase II Clinical Trial In Relapsed Or Refractory Classical Hodgkin Lymphoma In Blood
7/18/2016
-
Takeda <And The Crohn's and Colitis Foundation of America Partner To Introduce 'IBD Unmasked' A First-Of-Its-Kind Awareness Campaign
7/13/2016
-
TiGenix Lands $400 Million+ Crohn's Disease Deal with Pharma Giant Takeda
7/6/2016
-
Takeda Receives European Commission (EC) Approval Of ADCETRIS (Brentuximab Vedotin) For Consolidation Treatment In Post-Transplant Hodgkin Lymphoma
7/6/2016
-
Takeda To Partner With Altos Therapeutics To Develop Promising Compound For The Treatment Of Gastroparesis
7/5/2016
-
Takeda Submits A New Drug Application For Novel, Oral Proteasome Inhibitor Ixazomib In Japan
7/5/2016
-
Takeda To Partner With Altos Therapeutics To Develop Promising Compound For The Treatment Of Gastroparesis
7/1/2016
-
Former Execs at Acerus and Takeda Land New Gigs at Merus
7/1/2016
-
Exosome Diagnostics Enters Partnership With Takeda
6/30/2016
-
Takeda Returns Certain Molecules, Products to Amgen
6/27/2016
-
TB Alliance And Takeda Announce Advancement Of Joint Program Investigating Promising Compounds For Novel TB Therapies Through Global Health Innovative Technology Fund
6/22/2016
-
Takeda Initiates World’s First Norovirus Vaccine Field Trial
6/20/2016
-
Tri-Institutional Therapeutics Discovery Institute Expands Partnership With Takeda Pharmaceuticals
6/17/2016
-
Takeda And M2Gen Collaborate With ORIEN To Speed Clinical Development And Discovery Of Cancer Treatments Through Health Informatics
6/16/2016
-
Takeda Release: Examine Trial Post-Hoc Analyses Of Mortality Data Regarding Cardiovascular Safety Of Alogliptin Presented At American Diabetes Association’s 76th Scientific Sessions And Published In Diabetes Care
6/13/2016
-
Takeda, Theravance Biopharma Strike $125 Million Deal for TD-8954
6/8/2016
-
Ultragenyx Forges $65 Million Rare Disease Pact with Takeda
6/7/2016
-
Takeda To Present New Data At The American Diabetes Association's 76th Scientific Sessions
6/6/2016
-
Former Medivation CMO Takes Helm at Roivant Sciences-Takeda's Newly Launched Company Myovant Sciences
6/6/2016
-
Sangamo CEO to Retire, GlaxoSmithKline-Takeda Exec to Take Helm
6/1/2016